Management will conduct a live presentation and question-and-answer session beginning at 4:30 PM ET. Interested participants are encouraged to dial in ten minutes before the start of the webcast. An archived recording of the proceedings will be made available through the Investor Relations section of the company's website shortly after the event concludes.

CytoSorbents continues to focus on its proprietary polymer bead technology, designed to remove toxic substances from blood during critical care procedures. While its flagship product, CytoSorb, is widely used across Europe and international markets, the company remains in the development phase for its DrugSorb-ATR system within the United States and Canada. Investors will be looking for updates on the firm’s regulatory progress and its broader strategy to reach operating cash-flow break-even during the latter half of 2026.